Much of that money will be used to back a Phase IIb study of the biotech's lead drug, Glymera, an experimental diabetes drug.
Fresh from advancing an experimental diabetes therapy into the clinic, Malvern, PA-based PhaseBio Pharmaceuticals has nailed down the second tranche of its $25 million Series B. New Enterprise
Research Triangle Park, NC-based PhaseBio Pharmaceuticals has raised $25 million in a Series B financing round. New investors New Enterprise Associates and OSI Investment Management, a subsidiary of